Kura Oncology (FRA:KUR) FCF Margin %: -470.76% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KUR Kura Oncology Inc FRA:KUR
36 GF Score
Price €9.84
! 7 Warning Signs
View Full Analysis

What is Kura Oncology FCF Margin %?

Kura Oncology FRA:KUR -5.38% 36 FCF Margin % is -470.76% as of Mar. 2026. GuruFocus rates FRA:KUR with a GF Score™ of 36/100. The stock has 7 warning signs investors should review. Among 950 Biotechnology companies, Kura Oncology ranks worse than 54.74% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kura Oncology's Free Cash Flow for the three months ended in Mar. 2026 was €-74.38 Mil. Kura Oncology's Revenue for the three months ended in Mar. 2026 was €15.80 Mil. Therefore, Kura Oncology's FCF Margin % for the quarter that ended in Mar. 2026 was -470.76%.

As of today, Kura Oncology's current FCF Yield % is -8.72%.

The historical rank and industry rank for Kura Oncology's FCF Margin % or its related term are showing as below:

FRA:KUR' s FCF Margin % Range Over the Past 10 Years
Min: -119.12   Med: 71.82   Max: 248.4
Current: -119.12

During the past 12 years, the highest FCF Margin % of Kura Oncology was 248.40%. The lowest was -119.12%. And the median was 71.82%.

FRA:KUR's FCF Margin % is ranked worse than
54.74% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs FRA:KUR: -119.12

Kura Oncology FCF Margin % Related Terms

Kura Oncology FCF Margin % Historical Data

* Premium members only.

The historical data trend for Kura Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology FCF Margin % Chart

Kura Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 248.40 -104.76

Kura Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -511.89 -197.77 -400.93 663.08 -470.76

FRA:KUR vs REPL, AVTX, SANA: FCF Margin % Comparison

For the Biotechnology subindustry, Kura Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kura Oncology FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's FCF Margin % falls into.


FRA:KUR
36GF Score
Kura Oncology Inc FRA:KUR
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kura Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kura Oncology's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-60.375/57.63
=-104.76 %

Kura Oncology's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-74.375/15.799
=-470.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -470.76% mean?
Kura Oncology (FRA:KUR) has a FCF Margin % of -470.76% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #520 out of 950 companies in the Biotechnology industry, placing it in the top 54.7%.
Is Kura Oncology's FCF Margin % too high?
Kura Oncology's current FCF Margin % is -470.76%. Based on the distribution chart, Kura Oncology ranks #520 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kura Oncology has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's FCF Margin % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #520 out of 950 companies for FCF Margin %. This places Kura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kura Oncology and its competitors. Kura Oncology's current FCF Margin % is -470.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (FRA:KUR) has a current FCF Margin % of -470.76%. The current FCF Margin % is -470.76%. Kura Oncology's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kura Oncology (FRA:KUR), the current FCF Margin % is -470.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Other Exchanges KURA:USA
Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
36GF Score

Get the complete analysis for FRA:KUR

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.84
Price